Selank

ID: selank

Aliases: Thr-Lys-Pro-Arg-Pro-Gly-Pro, tuftsin analog, SELANK

Type: compound

Route/form: intranasal in regional clinical/research literature; formulation varies by study and region

Status: regional_or_research

Evidence level: early human

Best data tier: human controlled/review

Support scope: human, non-human/mechanistic

Source types: human_rct, preclinical

Linked sources: 3

Broad outcomes: Brain / mood / sleep, Gut / immune / inflammation

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• tuftsin-derived immunopeptide signaling
• GABAergic/monoaminergic modulation hypotheses
• anxiolytic pathway hypotheses

Optimization domains

• anxiety
• cognition
• immune
• nootropic
• CNS

Research basis

• Mechanism and human-optimization relevance are retained only where backed by scientific sources.

Limits, risks, and missing evidence

• Evidence quality and generalizability are weaker than for standard anxiolytics, and much of the literature is regional/older or preclinical.

Risk flags

• regional evidence
• limited human data
• CNS
• intranasal delivery uncertainty
• unapproved context

Linked papers, labels, and reviews

1. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in generalized anxiety disorders and neurasthenia
   human_rct / pubmed_selank_gad_2008
   Russian comparative clinical study in GAD/neurasthenia; regional evidence and translation caveats apply.
2. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank
   preclinical / pubmed_selank_immune_gene_expression_2011
   Mouse spleen inflammatory-gene-expression study for Selank and fragments.
3. Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank
   preclinical / pubmed_selank_transcriptome_2013
   Rat hippocampus transcriptome study after intranasal Selank exposure.